주식회사바오젠
주식회사바오젠's KOBDi Score is 45.57 as of Sep 2026, down 1.03 points since Apr 2025; it rose in 5 and fell in 2 of the 12 monthly updates. As of Sep 2026 it is ahead of about 60% of companies in its industry, against 59% in Aug 2026 and 34% in Apr 2025. Its strongest position was 60% (Sep 2026) and its weakest 34% (Aug 2025).
A year earlier, in Aug 2025, its score was 45.16 and it was ahead of about 34% of companies in its industry.
| Sep 2026 | 45.57 | ahead of 60% |
| Aug 2026 | 45.42 | ahead of 59% |
| Jul 2026 | 45.42 | ahead of 60% |
| Jun 2026 | 45.26 | ahead of 60% |
| May 2026 | 43.36 | ahead of 56% |
| Apr 2026 | 43.36 | ahead of 57% |
| Mar 2026 | 45.19 | ahead of 59% |
| Feb 2026 | 45.16 | ahead of 60% |
| Dec 2025 | 45.16 | ahead of 60% |
| Aug 2025 | 45.16 | ahead of 34% |
| Jul 2025 | 44.96 | ahead of 34% |
| May 2025 | 44.96 | ahead of 34% |
| Apr 2025 | 46.60 | ahead of 34% |
Where is 주식회사바오젠 located?
주식회사바오젠 is registered at 충청남도 천안시 동남구 천안대로, South Korea (postal code 31212).
What industry is 주식회사바오젠 in?
주식회사바오젠 belongs to Manufacturing › Pharmaceuticals & Biologics › Manufacturing of medicinal compounds and antibiotics.
How many employees does 주식회사바오젠 have?
주식회사바오젠 has 5–9 employees.
What is 주식회사바오젠's KOBDi Score?
45.57 as of September 2026, ahead of about 60% of companies in its industry.
Who are 주식회사바오젠's competitors?
Similar companies include 동국제약주식회사, 주식회사 헤파톨 and ONCOBIX.

